CatEyePerspective
- The Committee for Medicinal Products for Human Use (OTC:CHMP) of the European Medicines Agency has recommended marketing approval for Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) updated COVID-19 vaccine, Comirnaty KP.2.
- If approved by the European Commission, the jab is indicated for individuals 6 months and older.
- The KP.2-adaped shot is also effective against the LB.1, KP.3 and KP.3.1.1 variants.
- The latest CDC data shows that 52.7% of current cases in the U.S. are from the KP.3.1.1 variant.